{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:25:13Z","timestamp":1761895513982},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,15]]},"DOI":"10.2146\/ajhp110644","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T16:10:26Z","timestamp":1341331826000},"page":"1184-1186","source":"Crossref","is-referenced-by-count":12,"title":["Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance"],"prefix":"10.1093","volume":"69","author":[{"given":"Jessica E.","family":"Freshour","sequence":"first","affiliation":[{"name":"Bill Gatton College of Pharmacy East Tennessee State University P.O. Box 70657 Johnson City, TN 37614"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna Q.","family":"Hudson","sequence":"additional","affiliation":[{"name":"Colleges of Pharmacy and Medicine University of Tennessee Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy B.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Family Medicine University of Tennessee Graduate School of Medicine Knoxville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea S.","family":"Franks","sequence":"additional","affiliation":[{"name":"Colleges of Pharmacy and Medicine University of Tennessee Health Science Center Knoxville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041203504784600_b1-0691184","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options: why the FDA approved a higher but not lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N Engl J Med."},{"key":"2019041203504784600_b2-0691184","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"2019041203504784600_b3-0691184","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J."},{"key":"2019041203504784600_b4-0691184","volume-title":"Pradaxa (dabigatran etexilate) package insert","year":"2011"},{"key":"2019041203504784600_b5-0691184","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1161\/CIRCULATIONAHA.110.973735","article-title":"Dabigatran and warfarin in vitamin K antagonist-na\u00efve and -experienced cohorts with atrial fibrillation","volume":"122","author":"Ezekowitz","year":"2010","journal-title":"Circulation."},{"key":"2019041203504784600_b6-0691184","unstructured":"European Medicines Agency. Pradaxa EPAR. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000829\/WC500041060.pdf (accessed 2011 Jul 22)."},{"key":"2019041203504784600_b7-0691184","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"2019041203504784600_b8-0691184","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1532-5415.1988.tb02383.x","article-title":"Commonly used methods of estimating creatinine clearance are inadequate for elderly debilitated nursing home patients","volume":"36","author":"Drusano","year":"1988","journal-title":"J Am Geriatr Soc."},{"key":"2019041203504784600_b9-0691184","unstructured":"Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling, 1998. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072127.pdf (accessed 2011 Jul 21)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/14\/1184\/28361458\/ajhp1184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T19:41:20Z","timestamp":1555098080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/14\/1184\/5111886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,15]]},"references-count":9,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,7,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110644","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,7,15]]},"published":{"date-parts":[[2012,7,15]]}}}